The information contained herein is intended for Healthcare Professionals (HCP) located in countries where Ozurdex® (dexamethasone 0.7mg) has been approved only. All other participants are required to exit this page. Materials are developed under UK product license. A list of countries with this product/ indication is available from UK_Medinfo@Allergan.com. Registration conditions and licenses differ internationally, please refer to your country Summary of Product Characteristics and Prescribing Information. By accessing the information, you confirm that you are an HCP and are located in a country where Ozurdex® has been approved.
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
About Allergan Eye Care
As a leader in eye care, Allergan has discovered, developed, and delivered some of the most innovative products in the industry for more than 70 years. Allergan has launched over 125 eye care products and invested billions of dollars in new treatments for the most prevalent eye conditions, including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein occlusion.